J. Browning

发表

Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients

L. Old, I. Davis, J. Cebon, 2006, Journal of immunotherapy.

Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.

R. Tothill, S. Fox, D. Etemadmoghadam, 2019, The Journal of clinical investigation.

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.

Lisa M. Ebert, I. Davis, J. Cebon, 2017, Immunotherapy.

A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors

S. Fox, S. Lade, A. Gill, 2020, Laboratory Investigation.

NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus

D. Altman, V. Cerundolo, P. Nathan, 2015, International journal of cancer.

ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.

Stephen B. Fox, Huiling Xu, S. Stuart, 2021, Pathology.

Distinctive localization of antigen-presenting cells in human lymph nodes.

Oliver Horlacher, T. John, J. Cebon, 2009, Blood.

Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

Lisa M. Ebert, I. Davis, J. Cebon, 2009, Clinical Cancer Research.

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

L. Old, I. Davis, J. Cebon, 2011, Cancer Immunology, Immunotherapy.

Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1

Yao-Tseng Chen, L. Old, I. Davis, 2004, Clinical Cancer Research.

Interferons and rheumatoid arthritis: insight into interferon biology?

J. Browning, 1987, Immunology today.

Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma

M. Madigan, J. Cebon, R. Conway, 2011, British Journal of Ophthalmology.

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells

C. Gedye, I. Davis, D. Corbeil, 2009, Cancer Immunology, Immunotherapy.

A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History

S. Fox, J. Desai, S. Luen, 2020, International journal of surgical pathology.

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage

I. Davis, A. Jungbluth, J. Cebon, 2006, Clinical Cancer Research.

The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.

Lisa M. Ebert, C. Gedye, D. Moss, 2008, Cancer research.

Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens

I. Davis, E. Lim, J. Cebon, 2006, Melanoma research.

Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.

R. Scolyer, I. Davis, R. Murali, 2011, European journal of cancer.

Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-11

N. Mifsud, L. Old, I. Davis, 2006, The Journal of Immunology.

ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non–Small Cell Lung Cancer

A. Simpson, Yao-Tseng Chen, N. Altorki, 2008, Clinical Cancer Research.

Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody.

B. Wood, D. McNaughton, I. Davis, 2007, Tissue antigens.